Introduction
============

The worldwide incidence of hepatocellular carcinoma (HCC) exceeds 600,000 patients per year, and is still rising.[@b1-cmar-5-337] An important characteristic of HCC is the predominant occurrence in liver cirrhosis and advanced chronic liver disease.[@b1-cmar-5-337] This explains why overall prognosis remains poor, as survival may depend on impaired liver function rather than tumor progression in some patients, and therapeutic options often are limited by potential hepatotoxicity.[@b1-cmar-5-337],[@b2-cmar-5-337]

The Barcelona Clinic Liver Cancer (BCLC) therapeutic algorithm takes this into account by combining tumor stage, clinical performance status, and liver function to stratify prognosis and treatment.[@b3-cmar-5-337],[@b4-cmar-5-337] Early stages (BCLC 0 and BCLC A) are characterized by limited tumor size and preserved liver function, while intermediate- (BCLC B), advanced- (BCLC C), and end-stage (BCLCD) cancer are defined by extended tumor size and decreased liver function. Consequently, surgical (resection or transplantation) or percutaneous thermal therapies (radiofrequency or microwave ablation) are mainly considered suitable for the early stage, while interventional therapies (transarterial chemo- or radioembolization) are applied in patients with intermediate-stage HCC. Systemic treatment with the tyrosine-kinase inhibitor sorafenib is considered the treatment of choice for patients with advanced-stage HCC. Patients with BCLC stage D do not benefit from cancer treatment, and thus are being considered for best supportive care only. Thus, recent strategies have focused on the establishment of new drugs for patients with advanced-stage HCC. Moreover, selected current trials focus on adjuvant pharmacological treatment options in early stage HCC or combination of interventional therapies and sorafenib in intermediate-stage HCC.

The development of efficient new drugs in HCC is challenged by the need for a safety profile, defined by low or absent hepatotoxicity and nephrotoxicity. Moreover, putative accumulation of the agent and its metabolites in patients with impaired liver and/or kidney function has to be taken into account and must be avoided.

Theoretically, HCC should be prone to inhibition of angiogenesis because it is a highly vascular tumor, and hypervascularization is an essential characteristic of HCC, closely linked to carcinogenesis and progression.[@b5-cmar-5-337]--[@b7-cmar-5-337] Indeed, antiangiogenic treatment of HCC, either by mechanical destruction of arterial tumor vessels after transarterial chemoembolization (TACE) or by pharmacological inhibition with the dual-kinase inhibitor sorafenib, which is still the only systemic agent approved for HCC, is the current basis of noncurative approaches in HCC.[@b8-cmar-5-337]--[@b12-cmar-5-337] So far, antiangiogenic tyrosine-kinase inhibitors other than sorafenib have failed in randomized placebo-controlled pivotal trials, due to either minor efficacy or unacceptable toxicity profiles. This review gives a critical overview of established antiangiogenic drugs and those currently being developed, and strategies with special focus on safety in intermediate- and advanced-stage HCC.

Angiogenesis in liver cirrhosis and HCC
=======================================

Angiogenesis is closely related to chronic hepatitis and hepatic fibrogenesis, which in turn may lead to liver cirrhosis and HCC. The vascular endothelial growth-factor (VEGF) pathway was identified as the major driver in tumor angiogenesis. However, activation and/or upregulation of abundant proangiogenic signaling pathways may lead to resistance to VEGF-based antiangiogenic therapy, reinducing tumor angiogenesis and subsequently resulting in tumor progression.[@b5-cmar-5-337] VEGF is crucially involved in angiogenesis, as well as in fibrogenesis in chronic liver disease, but other cytokines, growth factors, and metalloproteinases are additionally involved in these processes.[@b13-cmar-5-337] HCC nodules larger than 2 cm typically show early arterial enhancement, a surrogate of hypervascularization, which is pathognomonic for HCC.[@b6-cmar-5-337],[@b7-cmar-5-337] In patients with HCC, higher VEGF serum levels were associated with poor outcome in the majority of but not all studies addressing this issue.[@b14-cmar-5-337]--[@b19-cmar-5-337] Moreover, increased expression of angiopoietin 1/2 messenger RNA in tumor tissue, another proangiogenic factor, has been reported in patients with HCC.[@b20-cmar-5-337] Therefore, it may be concluded that angiogenesis in HCC is a complex process and most likely heterogeneous.

Sorafenib in advanced hepatocellular carcinoma
==============================================

The proof of concept that pharmacological inhibition of angiogenesis is clinically meaningful in HCC was provided by four clinical trials showing consistently a survival benefit of approximately 3 months in patients with advanced HCC and preserved liver function treated with sorafenib, which is still the only systemic agent approved for advanced HCC.[@b21-cmar-5-337]--[@b24-cmar-5-337] Sorafenib is a multikinase inhibitor with activity against VEGF receptor (VEGFR)-2, platelet-derived growth-factor receptor (PDGFR), receptor of the tyrosine kinase c-Kit, rapidly accelerated fibrosarcoma B kinase, and mitogen-activated protein kinase p38 signal-transduction pathways, which seem to be involved in the pathogenesis of HCC.[@b8-cmar-5-337] The main effect of sorafenib is disease stabilization, and sorafenib can be used with an acceptable safety profile under daily practice conditions.[@b25-cmar-5-337],[@b26-cmar-5-337] However, adverse effects -- mainly fatigue, diarrhea, and hand--foot syndrome -- may significantly alter quality of life and may lead to dose reduction of sorafenib.[@b21-cmar-5-337]--[@b26-cmar-5-337] Within a recent Phase II study, dose escalation of sorafenib was not superior to best supportive care in patients with advanced HCC and disease progression during sorafenib 400 mg twice daily, while adverse events (diarrhea 80%, weight loss 75%, fatigue 67%, hand--foot skin reaction 49%, abdominal pain 37%, stomatitis 26%) were common.[@b27-cmar-5-337]

Antiangiogenic drugs in clinical development
============================================

A consequent step of antiangiogenic drug development was to investigate tyrosine-kinase inhibitors with other or additional targets than sorafenib in HCC. Sunitinib, a tyrosine-kinase inhibitor targeting the tyrosine kinase Kit, PDGFR-α and -β, and VEGFR1, -2, and -3, was compared to sorafenib as first-line treatment of advanced HCC in the SUN1170 trial.[@b28-cmar-5-337] This trial was terminated early because of a higher rate of drug-related adverse events in the sunitinib arm, including fatal outcomes. Overall survival in patients taking sunitinib was 7.9 months compared to 10.2 months in the sorafenib arm. Linifanib, a selective VEGFR and PDGFR tyrosine-kinase inhibitor, was also investigated in first-line treatment of advanced HCC compared to sorafenib.[@b29-cmar-5-337] Linifanib was less effective than sorafenib, with a median overall survival of 9.1 months compared to 9.8 months in the sorafenib arm. A comparison of overall survival in current head-to-head Phase III studies investigating sorafenib, sunitinib, brivanib, linifanib, and erlotinib is given in [Figure 1](#f1-cmar-5-337){ref-type="fig"}.

Recently, it was shown that inhibition of the fibroblast growth-factor receptor (FGFR)-4 pathway is involved in HCC development in a mouse model.[@b30-cmar-5-337] Brivanib, a selective dual inhibitor of VEGFR and FGFR,[@b31-cmar-5-337] was shown to have antitumor activity in patients with advanced HCC in two open-label Phase II studies.[@b32-cmar-5-337],[@b33-cmar-5-337] Unfortunately, brivanib was not superior compared to placebo in patients after sorafenib-treatment failure or intolerance to sorafenib in a Phase III study.[@b34-cmar-5-337] In another Phase III trial comparing brivanib and sorafenib as first-line treatment in advanced HCC, brivanib failed to prove noninferiority in comparison to sorafenib. Moreover, serious adverse events were common in both the brivanib (59%) and sorafenib (52%) treatment arms.[@b35-cmar-5-337] Therefore, the development of brivanib in HCC was stopped. Of note, the combination of sorafenib and the EGFR inhibitor erlotinib was not superior to sorafenib alone in terms of progression-free or overall survival.[@b1-cmar-5-337] Moreover, the toxicity profile of this combination was worse than that of sorafenib alone. The results of recent clinical trials in advanced HCC are summarized in [Table 1](#t1-cmar-5-337){ref-type="table"}.

Toxic effects of antiangiogenic therapy in HCC
==============================================

Based on the clinical trial experience of the last few years with antiangiogenic agents in HCC, certain "class" toxicity profiles have emerged. In HCC, as in other malignancies, these include hypertension, bleeding, thromboembolic events, and proteinuria. Some toxic effects are more specific for tyrosine-kinase inhibitors, eg, hand--foot skin reaction, rash, and diarrhea. In addition, a general problem of anti-angiogenic agents in HCC is the risk of worsening liver function, which might result in liver-enzyme elevation and fatigue, and more importantly in jaundice, hepatic encephalopathy, and ascites.

With sorafenib, these side effects are manageable.[@b21-cmar-5-337]--[@b24-cmar-5-337] However, especially in "dirty" kinase inhibitors, such as sunitinib, liver-specific toxicity seems to be even more prominent.[@b28-cmar-5-337] Therefore, a goal of future development of antiangiogenic agents in HCC is a manageable side-effect profile with a low incidence of liver-related toxicity.

Transarterial chemoembolization as antiangiogenic treatment
===========================================================

Hepatic tissue hypoxemia, amongst others, seems to be a relevant trigger for angiogenesis in chronic liver disease via induction of VEGF.[@b36-cmar-5-337] TACE was introduced into treatment algorithms for intermediate-stage HCC years before the approval of sorafenib. TACE may lead to reduction of tumor vascularization and viable tumor volume in HCC,[@b37-cmar-5-337],[@b38-cmar-5-337] and response to TACE is higher in patients with lower baseline VEGF serum levels.[@b39-cmar-5-337] Increased expression of VEGF after TACE has been reported, and development of satellite HCC nodules adjacent to TACE-treated lesions is a known clinical problem.[@b40-cmar-5-337]--[@b43-cmar-5-337] TACE-induced hypoxemia may therefore trigger the expression of angiogenic factors, ultimately resulting in tumor progression.[@b40-cmar-5-337]--[@b44-cmar-5-337] These observations form the rationale for combining TACE -- or other trans-arterial treatments -- with sorafenib, in order to prevent upregulation of VEGF. Several trials using a combination of sorafenib with lipiodol-based TACE, doxorubicin-eluting beads (DEB)-TACE, and selective internal radiation therapy (SIRT) have been reported ([Table 2](#t2-cmar-5-337){ref-type="table"}). The combination of sorafenib and TACE seems favorable in a subgroup of patients, but current data are controversial.[@b45-cmar-5-337]--[@b54-cmar-5-337] In a recent meta-analysis, the efficacy of DEB-TACE was reported to be comparable to lipiodol-based TACE.[@b55-cmar-5-337] The combination of sorafenib with DEB-TACE showed promising results in a Phase II trial.[@b56-cmar-5-337] However, in the SPACE trial, \[A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC)\], a randomized Phase II trial, the combination of sorafenib with DEB-TACE in intermediate-stage HCC was not meaningfully superior to DEB-TACE alone in terms of time to tumor progression and overall survival.[@b57-cmar-5-337] Moreover, the combination treatment was associated with an increased rate of toxicity, especially in Caucasian patients.[@b57-cmar-5-337] In contrast, a recent cohort study showed that DEB-TACE alone was safe and associated with a median survival of 48.6 months. Therefore DEB-TACE -- and also lipiodol-based TACE -- seems to be an alternative treatment in patients with BCLC A-stage HCC not feasible for resection, ablation, or liver transplantation.[@b58-cmar-5-337] Further studies still have to establish the role of sorafenib in combination with TACE.

Strategies to overcome resistance to antiangiogenic treatment
=============================================================

Since tumor angiogenesis is a complex process based not only on VEGF, but on a subtle interplay of intricately interweaved pathways, targeting different drivers of tumor angiogenesis might overcome antiangiogenic resistance. VEGFR2 is the critical receptor involved in tumor angiogenesis, with its activation inducing a number of other cellular modifications, resulting in tumor growth and metastases. Ramucirumab (IMC-1121B) is a fully human monoclonal antibody developed to specifically inhibit VEGFR2. Ramucirumab is currently being investigated in multiple clinical trials across a variety of tumor types, including a placebo-controlled Phase III trial in patients with HCC after failure of sorafenib. Results of this trial are expected early next year (<http://clinicaltrials.gov/show/NCT01140347>).

Another important regulator of vessel remodeling and maturation is the angiopoietin/Tie ligand/receptor system, which is an attractive therapeutic target in cancer.[@b59-cmar-5-337] In theory, angiopoietin inhibitors could inhibit tumor angiogenesis effi-ciently, but may lack typical tyrosine-kinase receptor inhibitor-associated toxicity. Currently, the selective angiopoietin 1/2-neutralizing peptibody AMG 386 is being investigated in combination with sorafenib in a Phase II trial in advanced or inoperable HCC (<http://www.clinicaltrials.gov/ct2/show/NCT00872014>). Completion of this study is also expected in the near future.

The most promising target in HCC is currently MET, a proto-oncogene that encodes a protein known as hepatocyte growth-factor receptor.[@b60-cmar-5-337],[@b61-cmar-5-337] Activation of MET signaling leads to tumor-cell growth, tumor-cell migration and invasion, and angiogenesis.[@b62-cmar-5-337] In HCC, aberrant MET signaling is frequently found, and MET overexpression is associated with advanced tumor stage and poor prognosis.[@b63-cmar-5-337]--[@b65-cmar-5-337] Tivantinib (ARQ 197) is an oral, selective MET tyrosine-kinase inhibitor that is developed in non-small-cell lung cancer, colorectal cancer, and HCC.[@b62-cmar-5-337],[@b66-cmar-5-337] Recent data from a randomized placebo-controlled Phase II study in advanced HCC after sorafenib failure demonstrated a benefit of patients with MET-high HCC only.[@b65-cmar-5-337] In this study, the median time to progression was 2.7 months in the tivantinib arm and 1.4 months in the placebo arm, and median overall survival was 7.2 months and 3.8 months, respectively, in the small group of patients with MET-high tumors. Of note, severe neutropenia developed in a substantial proportion of patients, and the dose of tivantinib was reduced from 360 mg to 240 mg for the further development of tivantinib in HCC. Recently, a randomized Phase III trial with tivantinib vs placebo in advanced MET-high HCC after failure of sorafenib was started (<http://clinicaltrials.gov/show/NCT01755767>). Cabozantinib, an oral inhibitor of RET ("rearranged during transfection"), VEGFR2, and MET is currently also being developed in a randomized Phase III trial in advanced HCC after sorafenib failure.

Further promising drugs that are under development for advanced HCC are the multiple tyrosine-kinase inhibitor dovitinib,[@b134-cmar-5-337] the oral histone-deacetylase inhibitor resminostat (<http://clinicaltrials.gov/show/NCT00943449>), and RO5137382 (GC33), a humanized anti-glypican-3 monoclonal antibody (<http://www.clinicaltrials.gov/ct2/show/study/> NCT01507168). An overview of current molecular targets and targeted drugs in HCC is given in [Figure 2](#f2-cmar-5-337){ref-type="fig"}. Another approach to overcome resistance to antiangiogenic therapy is combination of targeted therapy with other systemic agents ([Table 3](#t3-cmar-5-337){ref-type="table"}). Currently, the efficacy and safety of these combination therapies cannot comprehensively rated, since only data from Phase I and II studies have been reported.

Summary
=======

The multikinase inhibitor sorafenib is still the only approved drug for advanced HCC. Data concerning the combination of sorafenib with locoregional therapies are still controversial. Multiple clinical trials are currently investigating new antiangiogenic drugs, especially in patients after failure of sorafenib. Inhibition of VEGFR2, MET, or angiopoietin, either alone or in combination with sorafenib, are promising approaches that might ultimately improve the prognosis of advanced HCC.
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###### 

Efficacy of systemic targeted monotherapy in hepatocellular carcinoma according to current Phase I--III studies

  Author                                                                       Year   Phase   Investigational drug   n                           RR     DCR                                                   PFS/TTP                                              OS
  ---------------------------------------------------------------------------- ------ ------- ---------------------- --------------------------- ------ ----------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------
  O'Neil et al[@b68-cmar-5-337],[a](#tfn1-cmar-5-337){ref-type="table-fn"}     2009   II      AZD 6244               16                          0      37.5                                                  nr                                                   nr
  Schwartz et al[@b69-cmar-5-337],[b](#tfn2-cmar-5-337){ref-type="table-fn"}   2006   II      Bevacizumab            30                          6.7    57                                                    nr/6.4                                               nr
  Siegel et al[@b70-cmar-5-337],[b](#tfn2-cmar-5-337){ref-type="table-fn"}     2008   II      Bevacizumab            46                          13     65                                                    6.9/nr                                               12.4
  Boige et al[@b71-cmar-5-337]                                                 2012   II      Bevacizumab            43                          14     42                                                    nr                                                   nr
  Kim et al[@b72-cmar-5-337]                                                   2012   II      Bortezomib             35                          4      37                                                    nr/1.6                                               6.0
  Park et al[@b33-cmar-5-337]                                                  2011   II      Brivanib               55                          7.2    47.2                                                  2.7                                                  10.0
  Finn et al[@b32-cmar-5-337]                                                  2012   II      Brivanib               46                          4.3    45.7                                                  nr/2.7                                               9.8
  Johnson et al[@b35-cmar-5-337]                                               2012   III     Brivanib               1,155 (577 brivanib)        12     66                                                    nr/4.2                                               9.9
  Llovet et al[@b34-cmar-5-337]                                                2012   III     Brivanib               395 (263 brivanib)          11.5   71.2                                                  nr/4.2                                               9.4
  Gruenwald et al[@b73-cmar-5-337]                                             2007   II      Cetuximab              27                          0      44                                                    2.0/1.9                                              nr
  Zhu et al[@b74-cmar-5-337]                                                   2007   II      Cetuximab              30                          0      17                                                    1.4/nr                                               9.6
  Philip et al[@b75-cmar-5-337]                                                2005   II      Erlotinib              38                          9      50                                                    3.2/nr                                               13.0
  Thomas et al[@b76-cmar-5-337]                                                2007   II      Erlotinib              40                          0      43                                                    3.1/nr                                               6.25 (10.75)[c](#tfn3-cmar-5-337){ref-type="table-fn"}
  Shiah et al[@b77-cmar-5-337]                                                 2013   I       Everolimus             39                          nr     44.4/71.4[d](#tfn4-cmar-5-337){ref-type="table-fn"}   nr                                                   nr
  Zhu et al[@b78-cmar-5-337]                                                   2011   I/II    Everolimus             25                          4      44                                                    3.8/nr                                               8.4
  O'Dwyer et al[@b79-cmar-5-337]                                               2006   II      Gefitinib              31                          3      22.5                                                  2.8/nr                                               6.5
  Lin et al[@b80-cmar-5-337]                                                   2008   II      Imatinib               15                          0      13.3                                                  nr/nr                                                nr
  Bekaii-Saab et al[@b81-cmar-5-337]                                           2009   II      lapatinib              26                          0      40                                                    1.9/nr                                               12.6
  Ramanathan et al[@b82-cmar-5-337]                                            2009   II      lapatinib              40                          5      35                                                    2.3/nr                                               6.2
  Toh et al[@b83-cmar-5-337]                                                   2013   II      linifanib              44                          9.1    nr                                                    nr/3.7                                               9.4
  Cainap et al[@b29-cmar-5-337]                                                2013   III     linifanib              1,035 (1:1 randomization)   nr     nr                                                    nr/5.4                                               9.1
  Rizell et al[@b84-cmar-5-337]                                                2008   II      Sirolimus              21                          4.8    23.8                                                  nr/nr                                                6.5
  Furuse et al[@b23-cmar-5-337]                                                2008   I       Sorafenib              27                          4      83                                                    nr/4.9                                               15.6
  Abou-Alfa et al[@b22-cmar-5-337]                                             2006   II      Sorafenib              137                         2.2    33.6                                                  nr/4.2                                               9.2
  Yau et al[@b24-cmar-5-337]                                                   2009   II      Sorafenib              51                          8      18                                                    3.0/nr                                               5.0
  Llovet et al[@b21-cmar-5-337]                                                2008   III     Sorafenib              602 (299 sorafenib)         2.0    71                                                    nr/5.5                                               10.7
  Cheng et al[@b85-cmar-5-337]                                                 2009   III     Sorafenib              226 (150 sorafenib)         3.3    54                                                    nr/2.8                                               6.5
  Kudo et al[@b86-cmar-5-337]                                                  2011   III     Sorafenib              458 (229 sorafenib)         nr     nr                                                    nr/5.4[e](#tfn5-cmar-5-337){ref-type="table-fn"}     29.7
  Hoda et al[@b87-cmar-5-337]                                                  2008   II      Sunitinib              23                          6      35                                                    nr/nr                                                nr
  Zhu et al[@b88-cmar-5-337]                                                   2009   II      Sunitinib              34                          2.9    47                                                    3.9/4.1                                              9.8
  Faivre et al[@b89-cmar-5-337]                                                2009   II      Sunitinib              37                          2.7    35                                                    3.7/5.3                                              8.0
  Koeberle et al[@b90-cmar-5-337]                                              2010   II      Sunitinib              45                          2      40                                                    2.8/2.8                                              9.3
  Wörns et al[@b91-cmar-5-337]                                                 2010   II      Sunitinib              11                          nr     40                                                    nr/3.2                                               8.4
  Barone et al[@b92-cmar-5-337]                                                2013   II      Sunitinib              34                          11.8   44.1                                                  nr/2.8                                               5.8
  Cheng et al[@b28-cmar-5-337],[a](#tfn1-cmar-5-337){ref-type="table-fn"}      2011   III     Sunitinib              1,073 (529 sunitinib)       nr     nr                                                    3.6/4.1                                              8.1
  Pinter et al[@b93-cmar-5-337]                                                2008   I/II    Thalidomide            28                          0      7.1                                                   nr                                                   5.1
  Santoro et al[@b94-cmar-5-337]                                               2013   I       Tivantinib             21                          0      45                                                    nr/3.3                                               nr
  Santoro et al[@b95-cmar-5-337]                                               2013   II      Tivantinib             107 (71 tivantinib)         3      44                                                    1.5/1.6                                              6.6
  Kanai et al[@b96-cmar-5-337]                                                 2010   I/II    TSU-68                 35                          8.6    42.8                                                  nr/2.1                                               13.1
  Hsu et al[@b97-cmar-5-337]                                                   2012   II      Vandetanib             90 (67 vandetanib)          0      16.0; 5.3[f](#tfn6-cmar-5-337){ref-type="table-fn"}   1.7; 1.1[f](#tfn6-cmar-5-337){ref-type="table-fn"}   5.75;5.95[f](#tfn6-cmar-5-337){ref-type="table-fn"}

**Notes:**

Trial stopped

overlap of patient cohorts cannot be excluded from information provided

recorded from therapy start (recorded from diagnosis)

for weekly and daily treated cohorts, respectively

only patients with advanced HCC and response to TACE were included, and TTP did not differ significantly between sorafenib and placebo

for vandetanib 100 or 300 mg, respectively. For a better comparison of study results, efficacy according to RECIST criteria is given, as some studies used RECIST and some RECIST and modified RECIST criteria.

Adapted from Welker and Trojan.[@b67-cmar-5-337]

**Abbreviations:** DCR, disease-control rate (complete response + partial response + stable disease \[%\]); OS, overall survival (months) -- may differ between studies with respect to start point (start of therapy/diagnosis); PFS/TTP, progression-free survival/time to progression (months); RR, response rate (complete + partial response \[%\]); nr, not reported; TACE, transcatheter arterial chemoembolization; RECIST, Response Evaluation Criteria in Solid Tumors trial; HCC, hepatocellular carcinoma.

###### 

Efficacy of sorafenib and TACE or SIRT in hepatocellular carcinoma (sequential therapy not included), according to current Phase I and II studies

  Author                                                                         Year   Phase   Investigational drug                                              n                     RR                                              DCR                                             OS
  ------------------------------------------------------------------------------ ------ ------- ----------------------------------------------------------------- --------------------- ----------------------------------------------- ----------------------------------------------- -----------------------------------------------
  Britten et al[@b98-cmar-5-337]                                                 2012   I       Bevacizumab + TACE                                                30 (15 bevacicumab)   nr                                              nr                                              49
  Buijs et al[@b99-cmar-5-337]                                                   2013   II      Bevacizumab + TACE                                                25                    60                                              100                                             10.8
  Pawlik et al[@b100-cmar-5-337]                                                 2011   II      Sorafenib + DEB-TACE                                              35                    58                                              100                                             nr
  Cabrera et al[@b101-cmar-5-337]                                                2011   II      Sorafenib + DEB-TACE or SIRT                                      47                    56.1                                            68.2                                            18.5
  Lencioni et al[@b57-cmar-5-337]                                                2012   II      Sorafenib + DEB-TACE                                              307 (154 sorafenib)   nr                                              nr                                              nt
  Chow et al[@b102-cmar-5-337]                                                   2010   II      Sorafenib + SIRT                                                  35                    31.4                                            77.1                                            10.8
  Dufour et al[@b54-cmar-5-337]                                                  2010   I       Sorafenib + TACE                                                  14                    nr[a](#tfn10-cmar-5-337){ref-type="table-fn"}   nr[a](#tfn10-cmar-5-337){ref-type="table-fn"}   nr[a](#tfn10-cmar-5-337){ref-type="table-fn"}
  Erhardt et al[@b103-cmar-5-337]                                                2011   II      Sorafenib + TACE                                                  45                    2                                               77.8                                            18.5
  Wu et al[@b104-cmar-5-337]                                                     2012   II      Sorafenib + TACE                                                  35                    45.7                                            81.8                                            nr
  Qu et al[@b49-cmar-5-337]                                                      2012   II      Sorafenib + TACE                                                  45                    nr                                              nr                                              27
  Park et al[@b46-cmar-5-337]                                                    2012   II      Sorafenib + TACE                                                  50                    44                                              84                                              20.8
  Sieghart et al[@b105-cmar-5-337],[b](#tfn11-cmar-5-337){ref-type="table-fn"}   2012   I       Sorafenib + TACE                                                  15                    46.7                                            53.3                                            10.6
  Bai et al[@b51-cmar-5-337]                                                     2013   II      Sorafenib + TACE                                                  164                   9.7                                             58.5                                            7.5
  Chung et al[@b50-cmar-5-337]                                                   2013   II      Sorafenib + TACE                                                  147                   52.4                                            91.2                                            nr
  Duan et al[@b47-cmar-5-337]                                                    2012   II      Sorafenib + TACE/TAE[c](#tfn12-cmar-5-337){ref-type="table-fn"}   52                    nr                                              nr                                              12.0

**Notes:**

The primary objective of this prospective trial was evaluation of safety and tolerability of a continuous regimen of sorafenib combined with TACE

trial stopped prematurely due to safety reasons

transarterial chemoperfusion in patients with pulmonary metastasis. For a better comparison of study results, efficacy according to RECIST criteria is given, as some studies used RECIST and some RECIST and modified RECIST criteria.

Adapted from Welker and Trojan.[@b67-cmar-5-337]

**Abbreviations:** DEB-TACE, drug eluting beads--transarterial chemoembolization; DCR, disease-control rate (complete response + partial response + stable disease \[%\]); OS, overall survival (months) -- may differ between studies with respect to start point (start of therapy/diagnosis); RR, response rate (complete + partial response \[%\]); SIRT, selective internal radio therapy; nr, not reported; TAE, transarterial embolization; RECIST, Response Evaluation Criteria in Solid Tumors trial.

###### 

Efficacy of combination therapy with systemic acting agents and targeted therapy in hepatocellular carcinoma, according to current Phase I--II studies.

  Author                                                                          Year   Phase   Investigational drug         n    RR                                            DCR                                           PFS/TTP                                       OS
  ------------------------------------------------------------------------------- ------ ------- ---------------------------- ---- --------------------------------------------- --------------------------------------------- --------------------------------------------- ---------------------------------------------
  Hsu et al[@b106-cmar-5-337]                                                     2010   II      Bevacizumab/capecitabine     45   9                                             51                                            2.7/nr                                        5.9
  Sun et al[@b107-cmar-5-337]                                                     2011   II      Bevacizumab/CapOx            40   20                                            78                                            6.8/nr                                        9.8
  Thomas et al[@b108-cmar-5-337]                                                  2009   II      Bevacizumab/erlotinib        40   25                                            67.5                                          9.0/nr                                        15.7
  Kaseb et al[@b109-cmar-5-337]                                                   2012   II      Bevacizumab/erlotinib        59   24                                            80                                            7.2/nr                                        13.7
  Yau et al[@b110-cmar-5-337]                                                     2012   II      Bevacizumab/erlotinib        10   0                                             0                                             1.5/1.8                                       4.4
  Philip et al[@b111-cmar-5-337]                                                  2012   II      Bevacizumab/erlotinib        27   2.1                                           44.4                                          nr/3.0                                        9.5
  Govindarajan et al[@b112-cmar-5-337]                                            2012   II      Bevacizumab/erlotinib        21   nr                                            nr                                            nr/2.6                                        8.3
  Treiber et al[@b113-cmar-5-337]                                                 2012   II      Bevacizumab/everolimus       31   nr                                            nr                                            nr/5.8                                        13.3
  Zhu et al[@b114-cmar-5-337]                                                     2006   II      Bevacizumab/GemOx            33   18                                            42                                            5.3/nr                                        9.6
  Berlin et al[@b115-cmar-5-337]                                                  2008   II      Bortezomib/doxorubicin       39   2.3                                           25.6                                          2.4/nr                                        5.7
  Sanoff et al[@b116-cmar-5-337]                                                  2011   II      Cetuximab/CapOx              24   12.5                                          83                                            nr/4.5                                        4.4
  Louafi et al[@b117-cmar-5-337],[a](#tfn15-cmar-5-337){ref-type="table-fn"}      2007   II      Cetuximab/GemOx              35   24                                            4.5                                           nr/nr                                         9.2
  Asnacios et [@b118-cmar-5-337],[a](#tfn15-cmar-5-337){ref-type="table-fn"}      2008   II      Cetuximab/GemOx              45   20                                            40                                            4.7/nr                                        9.5
  Chiorean et al[@b119-cmar-5-337]                                                2012   II      Erlotinib/docetaxel          14   0                                             46                                            3.5/nr                                        6.7
  Luelmo et al[@b120-cmar-5-337]                                                  2012   II      Everolimus/capcitabine       10   0                                             40                                            3.4/nr                                        Nr
  Knox et al[@b121-cmar-5-337],[b](#tfn16-cmar-5-337){ref-type="table-fn"}        2008   II      G3139/doxorubicin            17   0                                             35                                            nr/1.8                                        5.4
  Yau et al[@b122-cmar-5-337]                                                     2010   I/II    PTK787/doxorubicin           27   26                                            46                                            5.4/nr                                        7.3
  Petrini et al[@b123-cmar-5-337]                                                 2012   II      Sorafenib/5-fluorouracil     38   3                                             48                                            nr/7.6                                        12.2
  Richly et al[@b124-cmar-5-337]                                                  2009   I       Sorafenib/doxorubicin        18   6.3                                           69                                            4.0/nr                                        Nr
  Abou-Alfa et al[@b125-cmar-5-337],[c](#tfn17-cmar-5-337){ref-type="table-fn"}   2010   II      Sorafenib/doxorubicin        96   4                                             77                                            6.9/8.6                                       13.7
  Dima et al[@b126-cmar-5-337]                                                    2009   II      Sorafenib/mitomycin C        22   27                                            77                                            nr                                            Nr
  Prete et al[@b127-cmar-5-337]                                                   2010   II      Sorafenib/octreotide         50   10                                            71                                            nr/7.0                                        12.0
  Abou-Alfa et al[@b128-cmar-5-337]                                               2011   I       Sorafenib/PR-104             14   7                                             50                                            nr                                            Nr
  Bitzer et al[@b129-cmar-5-337]                                                  2012   I/II    Sorafenib/resminostat        25   [d](#tfn18-cmar-5-337){ref-type="table-fn"}   [d](#tfn18-cmar-5-337){ref-type="table-fn"}   [d](#tfn18-cmar-5-337){ref-type="table-fn"}   [d](#tfn18-cmar-5-337){ref-type="table-fn"}
  Shen et al[@b130-cmar-5-337],[a](#tfn15-cmar-5-337){ref-type="table-fn"}        2008   II      Sorafenib/tegafur-uracil     40   13                                            58.3                                          3.7/nr                                        nr
  Hsu et[@b131-cmar-5-337],[a](#tfn15-cmar-5-337){ref-type="table-fn"}            2010   II      Sorafenib/tegafur-uracil     53   8                                             57                                            3.7/nr                                        7.4
  Hsu et al[@b132-cmar-5-337]                                                     2009   II      Thalidomide/tegafur-uracil   43   9.3                                           32.6                                          1.9/nr                                        4.6
  Zhu et al[@b133-cmar-5-337]                                                     2005   II      Thalidomide/epirubicin       19   0                                             41                                            6.0/nr                                        6.4

**Notes:**

Overlap of patient cohorts cannot be excluded from information provided in the abstracts

trial stopped due to lack of efficacy

trial stopped due to superiority of sorafenib

not reported for combination subgroup. For a better comparison of study results, efficacy according to RECIST criteria is given, as some studies used RECIST and some RECIST and modified RECIST criteria. © 1995--2013 Baishideng Publishing Group Co., Limited. Adapted with permission from Welker MW, Trojan J. Anti-angiogenesis in hepatocellular carci noma treatment: current evidence and future perspectives. *Word J Gastroenterol*. 2011;17:3075--3081.[@b67-cmar-5-337]

**Abbreviations:** DCR, disease-control rate (complete response + partial response + stable disease \[%\]); GemOx, gemcitabine and oxaliplatin; nr, not reported; OS, overall survival (months) -- may differ between studies with respect to start point (start of therapy/diagnosis); PFS/TTP, progression-free survival/time to progression (months); RR, response rate (complete + partial response \[%\]); CapOx, capecitabine and oxaliplatin; RECIST, Response Evaluation Criteria in Solid Tumors trial; nr, not reported; HCC, hepatocellular carci noma; nr, not reported.
